References
- CondeLRibyJZhangJBracciPMSkibolaCFCopy number variation analysis on a non-Hodgkin lymphoma case-control study identifies an 11q25 duplication associated with diffuse large B-cell lymphomaPLoS One201498e10538225133503
- KwiecinskaAIchimuraKBerglundMAmplification of 2p as a genomic marker for transformation in lymphomaGenes Chromosomes Cancer201453975076824832791
- CuiWCaiYWangWFrequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphomaJ Transl Med2014121024418330
- MondelloPYounesAEmerging drugs for diffuse large B-cell lymphomaExpert Rev Anticancer Ther201515443945125652253
- JardinFNext generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapyDiscov Med20141897516525091488
- XuZZXiaZGWangAHActivation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximabAnn Hematol201392101351135823636313
- PfeiferMLenzGPI3K/AKT addiction in subsets of diffuse large B-cell lymphomaCell Cycle201312213347334824091535
- RahmaniMAustMMBensonECWallaceLFriedbergJGrantSPI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivoClin Cancer Res201420184849486025070836
- WaibelMGregoryGShorttJJohnstoneRWRational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphomaCurr Opin Hematol201421429730824811162
- ZangCEuckerJLiuHInhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphomaLeuk Lymphoma201455242543423721513
- UddinSHussainARSirajAKRole of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survivalBlood2006108134178418616946303
- AbubakerJBaviPPAl-HarbiSPIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphomaLeukemia200721112368237017657213
- BaohuaYXiaoyanZTiechengZTaoQDarenSMutations of the PIK3CA gene in diffuse large B cell lymphomaDiagn Mol Pathol200817315916518382359
- MullerCIMillerCWHofmannWKRare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogeneLeuk Res2007311273216764926
- MarincevicMTobinGRosenquistRInfrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemiaLeuk Lymphoma200950582983019330652
- IyengarSClearABodorCP110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapseBlood2013121122274228423341541
- AdamsJRXuKLiuJCCooperation between Pik3ca and p53 mutations in mouse mammary tumor formationCancer Res20117172706271721324922
- TabeYJinLKonoplevaMClass IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphomaActa Haematol20141311596924052005
- ZhaiLZhaoYYeSExpression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue typeTumour Biol201132591392021660567
- KaplanRMChambersDAGlasgowREBig data and large sample size: a cautionary note on the potential for biasClin Transl Sci20147434234625043853
- BakerMReproducibility crisis: blame it on the antibodiesNature2015521755227427625993940
- OhSKooDHSuhCPrognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapyJ Korean Med Sci201126121556156222147991
- LinderothJEhingerMAkermanMTissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphomaEur J Haematol200779214614917635238